Form 4: Taysha Gene Therapies CFO Kamran Alam Reports Tax-Related Stock Disposal
SEC Form 4 Filing
Chief Financial Officer of Taysha Gene Therapies, Kamran Alam, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On March 11, 2025, Kamran Alam, the CFO of Taysha Gene Therapies, disposed of 29,843 shares of common stock to cover tax withholding obligations.
- The transaction was not discretionary and was executed at a price of $1.69 per share.
- Following the transaction, Alam directly owns 1,242,094 shares of Taysha Gene Therapies.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock transaction for tax purposes, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small percentage of the CFO's holdings.
Key Dates
| Date | Description |
|---|---|
| 03/11/2025 | Date of stock disposal transaction. |
| 03/12/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.